CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Bortezomib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01833143
NCT01833143Phase 2Completed
CompareCT.gov

A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Memorial Sloan Kettering Cancer Center·interventional·Posted Apr 16, 2013·Updated Aug 4, 2020

In Brief

A Phase 2 clinical trial evaluating Bortezomib and Acyclovir for Non-Small Cell Lung Cancer. Completed, enrolled 17 participants across 5 sites.

Detailed Summary

The purpose of this study is to test the drug Bortezomib to see how well it works. The investigators want to find out what effects, good or bad, it has on patients with a limited smoking history or who have a specific mutation associated with their lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2013
Enrollment StartApr 11, 2013
Primary CompletionAug 28, 2019
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 13.2 years ago

Interventions

Bortezomibdrug

Acyclovirdrug